Richard Rhiew, MD
Internal Medicine · Green Valley, AZNPI 1346226479
Payments from drug & device makers
Across 283 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$553
- Lilly USA, LLC$524
- Amgen$518
- GSK$511
- AstraZeneca$361
- Novartis$191
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,564100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $553 |
| Lilly USA, LLC | 30 | $524 |
| Amgen | 38 | $518 |
| GSK | 36 | $511 |
| AstraZeneca | 20 | $361 |
| Novartis | 10 | $191 |
| Sumitomo Pharma America, Inc. | 10 | $190 |
| Abbott | 3 | $182 |
| Pfizer | 12 | $182 |
| AbbVie | 8 | $160 |
| Astellas Pharma US Inc | 9 | $159 |
| Johnson & Johnson | 9 | $144 |
| Amarin Pharma, Inc. | 9 | $132 |
| Sanofi-aventis U.S. LLC | 6 | $107 |
| Merck | 4 | $79 |
| Radius Health, Inc. | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $77 |
| Kowa Pharmaceuticals America, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Boehringer Ingelheim | 3 | $43 |
| Boston Scientific | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Exact Sciences | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,582 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $116,028 |
| EliquisApixaban | 118 | $115,490 |
| RybelsusSemaglutide | 48 | $72,798 |
| OzempicSemaglutide | 41 | $61,205 |
| JardianceEmpagliflozin | 33 | $48,456 |
| FarxigaDapagliflozin Propanediol | 30 | $34,312 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $31,967 |
| XareltoRivaroxaban | 30 | $31,301 |
| MyrbetriqMirabegron | 25 | $25,873 |
| GemtesaVibegron | 29 | $20,549 |
| LinzessLinaclotide | 22 | $17,821 |
| MounjaroTirzepatide | 17 | $17,599 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,603 |
| Ezetimibe | 292 | $5,568 |
| Atorvastatin Calcium | 526 | $5,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $553 | $134,00489 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $511 | $128,845130 claims |
| PfizerEliquis | $182 | $115,490118 claims |
| Boehringer IngelheimJardiance | $43 | $48,45633 claims |
| AstraZenecaFarxiga | $361 | $34,31230 claims |
| Johnson & JohnsonXarelto | $144 | $31,30130 claims |
| Astellas Pharma US IncMyrbetriq | $159 | $25,87325 claims |
| AbbVieLinzess, Synthroid | $160 | $22,62997 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $190 | $20,54929 claims |
| Lilly USA, LLCMounjaro | $524 | $17,59917 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $5,161557 claims |
| Sanofi-aventis U.S. LLCLantus | $107 | $2,02927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Green Valley
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.